Helen J Gogas

37PUBLICATIONS
168CO-AUTHORS
Predictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Epidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Jan 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Reinhard Dummer, Shibing Deng, Tao Xie

|Nov 19, 2025
The Illusion of Residual Disease: An Unusual Pattern of Histologic Response to Neoadjuvant Immunotherapy in Resectable Stage III Melanoma.

Maria Kostaki, Roxani Kapranou, Ioannis Koutsinas

|Oct 18, 2025
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.

Georgina V Long, Charlie Garnett-Benson, Sonia Dolfi

|Jul 03, 2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047.

Evan J Lipson, Sonia Dolfi, Hao Tang

|Mar 27, 2025
Exploring the Dynamics of Immune Checkpoint Inhibitor-Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis.

Panagiotis T Diamantopoulos, Aikaterini Gkoufa, Amalia Anastasopoulou

|Dec 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.

Hussein A Tawbi, F Stephen Hodi, Evan J Lipson

Pageof 7